financetom
Business
financetom
/
Business
/
JPMorgan's profit jumps on dealmaking, trading boost
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
JPMorgan's profit jumps on dealmaking, trading boost
Apr 11, 2025 4:16 AM

(Reuters) - JPMorgan Chase's ( JPM ) first-quarter profit rose 9%, helped by higher fees from dealmaking and a record performance in equities trading.

Investment banking fees rose 12% while equity markets revenue surged 48% to a record of $3.8 billion, as business was largely buoyed by optimism in the first three months of 2025 that U.S. President Donald Trump would enact pro-growth policies, ease regulations and lower taxes.

Shares climbed 4% before the open.

However, the uncertainty surrounding the trade policy has upended those hopes and fueled market turbulence. Trump last week unveiled steep reciprocal tariffs on dozens of countries, only to pause many of them on Wednesday.

"Clients have become more cautious amid an increase in market volatility driven by geopolitical and trade-related tensions," CEO Jamie Dimon said. "The economy is facing considerable turbulence, including geopolitics."

JPMorgan ( JPM ) increased its provisions for credit losses to $3.3 billion from $1.9 billion last year. Consumers and businesses could struggle to repay their loans if new import levies reignite inflation and dampen economic growth.

"You'll see more credit problems," Dimon told Fox Business' "Mornings with Maria" program on Wednesday.

The heightened volatility due to shifting expectations lifted banks' trading business as investors quickly adjusted their portfolios.

Investment banking fees rose to $2.2 billion. Trading revenue climbed 21%, higher than the earlier expectations of a low double-digits percentage gain.

Earnings were $14.6 billion, or $5.07 a share, for the three months ended March 31, the biggest U.S. bank said on Friday. That compares with $13.4 billion, or $4.44 a share, a year earlier.

(Reporting by Niket Nishant in Bengaluru and Nupur Anand in New York, editing by Lananh Nguyen and Sriraj Kalluvila)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2025 - www.financetom.com All Rights Reserved